PDC-E2 Antibody (C-9): sc-271352

PDC-E2 Antibody (C-9) is a mouse monoclonal IgG1 antibody that detects PDC-E2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). PDC-E2 plays a crucial role in cellular metabolism as a component of the pyruvate dehydrogenase multienzyme complex, which is essential for converting pyruvate into acetyl-CoA, a key substrate for the citric acid cycle. This metabolic pathway is vital for energy production and the synthesis of fatty acids, making PDC-E2 integral to maintaining cellular energy homeostasis. PDC-E2′s structure includes both an amino-terminal lipoyl-bearing domain and a carboxy-terminal catalytic domain, with the lipoyl domain being particularly important for enzymatic function. The presence of specific autoantibodies against PDC-E2 in patients with primary biliary cirrhosis highlights PDC-E2′s significance in autoimmune responses, as these autoantibodies can lead to the destruction of biliary epithelial cells, ultimately affecting liver function. Anti-PDC-E2 antibody (C-9) is therefore a valuable tool for researchers studying metabolic disorders and autoimmune diseases, providing insights into PDC-E2′s role and interactions within the cellular environment.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PDC-E2 Antibody (C-9) References:

1. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis.  |  Shimoda, S., et al. 2000. Hepatology. 31: 1212-6. PMID: 10827144
2. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens.  |  Shigematsu, H., et al. 2000. Hepatology. 32: 901-9. PMID: 11050037
3. Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis.  |  Matsumura, S., et al. 2002. Hepatology. 36: 1125-34. PMID: 12395322
4. Characterization and epitope mapping of human monoclonal antibodies to PDC-E2, the immunodominant autoantigen of primary biliary cirrhosis.  |  Leung, PS., et al. 1992. J Autoimmun. 5: 703-18. PMID: 1283300
5. Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.  |  Bellucci, R., et al. 2007. Blood. 109: 2001-7. PMID: 17068145
6. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis.  |  Shimoda, S., et al. 2008. J Autoimmun. 31: 110-5. PMID: 18644699
7. Heterogeneity of combinatorial human autoantibodies against PDC-E2 and biliary epithelial cells in patients with primary biliary cirrhosis.  |  Cha, S., et al. 1994. Hepatology. 20: 574-83. PMID: 7521314
8. Analysis of T-cell receptor beta of the T-cell clones reactive to the human PDC-E2 163-176 peptide in the context of HLA-DR53 in patients with primary biliary cirrhosis.  |  Ichiki, Y., et al. 1997. Hepatology. 26: 728-33. PMID: 9303504
9. Immunogenetic analysis of a panel of monoclonal IgG and IgM anti-PDC-E2/X antibodies derived from patients with primary biliary cirrhosis.  |  Thomson, RK., et al. 1998. J Hepatol. 28: 582-94. PMID: 9566826
10. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis.  |  Sadamoto, T., et al. 1998. Lancet. 352: 1595-6. PMID: 9843108

The preferred PDC-E2 antibody is PDC-E2 Antibody (B-2): sc-271534.